Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

GRAIL, Inc.

NASDAQ: GRAL · Industrial Applications and Services · 6 alerts · CIK 1699031

Share price
$105.60Close, Nov 16
Market cap
$4.75B
Shares outstanding
44.96MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GRAIL, Inc. filings on SEC EDGAR ↗

9:10 PM ET Form 4
Insider Selling

GRAIL CFO Aaron Freidin Sells $323K of Stock

Aaron Freidin, CFO, sold 3,000 shares of GRAIL, Inc. at $104.97 to $112.53 a share (average $107.62) in 6 transactions, worth $323K in total on Nov 16, 2026. Shares held after the trade: 222,364 (-0.0%).

Value
$323K
Shares
3,000
Average price
$107.62
Role
CFO
Holding change
-0.0%
Trade date
Nov 16, 2026
4:12 PM ET 10-Q
Financial Results

GRAIL Q3 2026 Results: Net Loss of $104M, Loss Widens

For the nine months ended September 30, 2026, GRAIL reported total revenue of $123.0 million, a 19% increase year-over-year, primarily driven by screening revenue. The company recorded a net loss of $307.0 million, slightly improved from $309.2 million in the prior year, while maintaining a cash and marketable securities balance of approximately $788.7 million.

Key figure
Net loss $104M
4:06 PM ET 8-K
Financial Results

GRAIL Financial Results

GRAIL reported third quarter 2026 financial results, highlighted by a 14% year-over-year increase in Galleri test revenue to $37.3 million and a favorable FDA Advisory Committee vote for the Galleri multi-cancer early detection test. The company reported a net loss of $103.6 million for the quarter and maintains a cash position of $788.7 million as it anticipates an FDA approval decision by early Q1 2027.

“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee. This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”

Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL
4:50 PM ET Form 4
Insider Selling

GRAIL CEO Joshua J. Ofman Sells $2.74M of Stock

Joshua J. Ofman, CEO, sold 20,000 shares of GRAIL, Inc. at $133.12 to $138.79 a share (average $136.85) in 6 transactions, worth $2.74M in total on Oct 15, 2026. Shares held after the trade: 342,271 (-0.6%).

Value
$2.74M
Shares
20,000
Average price
$136.85
Role
CEO
Holding change
-0.6%
Trade date
Oct 15, 2026
6:37 PM ET Form 4
Insider Selling

GRAIL CFO Aaron Freidin Sells $3.46M of Stock

Aaron Freidin, CFO, sold 23,619 shares of GRAIL, Inc. at $146.39 a share, worth $3.46M in total on Oct 5, 2026. Shares held after the trade: 225,364 (-9.5%).

Value
$3.46M
Shares
23,619
Price
$146.39
Role
CFO
Holding change
-9.5%
Trade date
Oct 5, 2026
6:37 PM ET Form 4
Insider Selling

GRAIL Chief Growth Officer Andrew John Partridge Sells $1.15M of Stock

Andrew John Partridge, Chief Growth Officer, sold 7,873 shares of GRAIL, Inc. at $146.39 a share, worth $1.15M in total on Oct 5, 2026. Shares held after the trade: 155,865 (-4.8%).

Value
$1.15M
Shares
7,873
Price
$146.39
Role
Chief Growth Officer
Holding change
-4.8%
Trade date
Oct 5, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.